| Literature DB >> 32602848 |
Jianchu Wang1,2, Jian Pu1,2, Ying Zhang2,3, Tianwei Yao1,2, Zongjiang Luo1,2, Wenchuan Li1,2, Guidan Xu2,4, Juan Liu2, Wujun Wei2,4, Yibin Deng2,4,5.
Abstract
Extracellular communication mediated by exosomes in a tumor microenvironment can substantially affect tumor progression. However, the effect of exosomal long non-coding RNA SENP3-EIF4A1 on hepatocellular carcinoma (HCC) is still unclear. In this study, SENP3-EIF4A1 expressions in patients with HCC and healthy controls were detected and compared. Results showed that SENP3-EIF4A1 was significantly reduced in HCC tissues and exosomes from the plasma of patients with HCC (P<0.05) and was primarily encapsulated by exosomes. The patients with HCC and the healthy controls could be distinguished using exosomal SENP3-EIF4A1 (AUC=0.8028). The transfer of exosomal SENP3-EIF4A1 secreted by normal cells to HCC cells stimulated apoptosis and weakened the invasion and migration abilities of HCC cells to suppress their malignant biological behavior (P<0.05). Additionally, exosomal SENP3-EIF4A1 was capable of inhibiting tumor growth in vivo and modulating the expression of ZFP36 by competitively binding to miR-9-5p. In conclusion, exosomal SENP3-EIF4A1 is a new favorable biomarker for clinically detecting HCC, and SENP3-EIF4A1 can be transmitted by exosomes from normal cells to HCC cells to inhibit the in vitro and in vivo development of HCC. Thus, exosomal SENP3-EIF4A1 is involved in the communication between normal cells and HCC cells during the onset of HCC.Entities:
Keywords: SENP3-EIF4A1; biomarker; ceRNA; exosomes; hepatocellular carcinoma
Year: 2020 PMID: 32602848 PMCID: PMC7343467 DOI: 10.18632/aging.103302
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
The characteristics of the hepatocellular carcinoma cases and healthy controls.
| Age(years) (mean ± SD) | 0.8200 | ||
| <50 | 14 | 12 | |
| ≥50 | 36 | 38 | |
| Gender | 0.6709 | ||
| Male | 32 | 35 | |
| Female | 18 | 15 | |
| Drinking status | 0.8153 | ||
| Never | 13 | 11 | |
| Ever | 37 | 39 | |
| Tumor staging (TNM) | |||
| I/ II | 26 | - | - |
| III/ IV | 24 | - |
Fisher's exact test for all variables between HCC cases and controls
Figure 1Expression of plasma exosomal (A) Heatmap illustrating the 21 differentially expressed lncRNAs between HCC patients’ plasma exos and healthy control patients’ plasma exos. (B) Detection of SENP3-EIF4A1 in exos from plasma via qRT-PCR. (C) Receiver Operating Characteristic (ROC) curve for the SENP3-EIF4A1 to distinguish HCC cases from controls (Top). Receiver Operating Characteristic (ROC) curve for the SENP3-EIF4A1 to distinguish TNM I/II stage HCC cases from controls (bottom). (D) Determination of SENP3-EIF4A1 in tumor tissues and adjacent normal tissues via qRT-PCR. (E) SENP3-EIF4A1 is lowly expressed in HCC cells compared with HL-7702 cell line. (F) Micrographs and the size distribution of exos isolated from the plasma of HCC patients (left) and healthy controls (right) were detected using TEM (bars =200 nm) and NTA. (G) Detection of TSG101, CD63 and Grp94 in circulating exos via Western blotting. Results are shown as mean ± SD. *P<0.05. All of the experiments were performed in triplicate.
Clinicopathologic correlation of lncRNA SENP3-EIF4A1 expression in HCC tissues.
| All cases | 50 | 25 | 25 | |
| Age(years) | 0.7536 | |||
| < 50 | 14 | 6 | 8 | |
| ≥50 | 36 | 19 | 17 | |
| Gender | 0.7688 | |||
| Male | 32 | 15 | 17 | |
| Female | 18 | 10 | 8 | |
| Drinking status | 0.5202 | |||
| Never | 13 | 8 | 5 | |
| Ever | 37 | 17 | 20 | |
| Tumor size (cm) | 0.0421 | |||
| < 5 | 30 | 19 | 11 | |
| ≥ 5 | 20 | 6 | 14 | |
| Tumor stage (TNM) | 0.0465 | |||
| I/ II | 26 | 17 | 9 | |
| III/ IV | 24 | 8 | 16 | |
| Lymph node metastasis | 0.0378 | |||
| Yes | 18 | 5 | 13 | |
| No | 32 | 20 | 12 |
Total data from 50 HCC patients were analyzed. For the expression of SENP3-EIF4A1 was assayed by qRT-PCR, the median expression level was used as the cutoff. Data were analyzed by Fisher's exact test. P-value in bold indicates statistically significant.
Figure 2Effect of (A) Detection of the mRNA level of SENP3-EIF4A1 via qRT-PCR. (B) Examination of cell viability via CCK8 assays. (C) Determination of cell colony formation ability via a colony-forming growth assay. The colonies are counted and captured. (D) Representative images of migration assays of HuH7 and Hep3b cells (bars =100 μm). The cells are counted. Results are shown as mean ± SD. *P<0.05. All of the experiments were performed in triplicate.
Figure 3Exosomal (A) Detection of the normalized expression of SENP3-EIF4A1 in the medium of HL-7702, Hep3b and HuH7 cells receiving treatment with RNase (2μg/ml) alone or combined treatment with RNase (2μg/ml) and Triton X-100 (0.1%) for 20min via qRT-PCR. (B) Micrographs of exos separated from HL-7702 (left), HuH7 (middle) and Hep3b cells (right, bars=200 nm). (C) Examination of TSG101, CD63 and Grp94 in exos of cell lines via Western blotting. (D) Detection of exosomal SENP3-EIF4A1 of HL-7702, Hep3b and HuH7 via qRT-PCR. (E) Assessment of the fold change of SENP3-EIF4A1 between exos of HL-7702, Hep3b and HuH7 and their producer cells via qRT-PCR. (F) Exos from HL-7702 cells are labeled with PKH67; green represents PKH67, and blue represents nuclear DNAs stained by DAPI. Hep3b and HuH7 cells undergo 3 h of incubation with exos from HL-7702 cells. Results are shown as mean ± SD. *P<0.05. All of the experiments were performed in triplicate.
Figure 4Effect of exosomal Exosomes separated from HL-7702 cells transfected with SENP3-EIF4A1 overexpression plasmids or NC vectors are named SENP3-EIF4A1-Exos or NC-Exos, respectively. After extraction, their exosomes are added to the HuH7 and Hep3b cells for 24h. (A) Detection of the mRNA level of SENP3-EIF4A1 via qRT-PCR. (B) Detection of cell viability by a CCK8 assay. (C) Examination of cell colony formation ability by a colony-forming growth assay. The colonies are counted and captured. (D) Representative images of migration assays of HuH7 and Hep3b cells (bars =100 μm). The cells are counted. Results are shown as mean ± SD. *P<0.05. All of the experiments were performed in triplicate.
Figure 5(A) Cytoplasmic and nuclear levels of SENP3-EIF4A1 in HuH7 and Hep3b cells analyzed by qRT-PCR. (B) The RNA-FISH results verified that SENP3-EIF4A1 was distributed mostly in the cytoplasm in HuH7 cells. (C) MiR-9-5p expression in HCC tissues and adjacent normal tissues detected by qRT-PCR. (D) Bioinformatics evidence of binding of miR-9-5p onto 3'-UTR of SENP3-EIF4A1. (E) RIP experiments for the amount of SENP3-EIF4A1 and miR-9-5p in HuH7 and Hep3b cells. (F) Dual-luciferase reporter gene assay in HuH7 and Hep3b cells after transfection with negative control or miR-9-5p mimics, Renilla luciferase vector pRL-SV40 and the reporter constructs. Data are presented as mean ± SD. *P<0.05. All of the experiments were performed in triplicate.
Figure 6(A) The putative miRNA binding sites in the ZFP36 sequence. (B) Direct target sites verified by the dual-luciferase reporter gene assay. (C) ZFP36 expression in HCC tissues and adjacent normal tissues detected via qRT-PCR. (D) Bivariate correlation analysis of the relationship between SENP3-EIF4A1 and ZFP36 expression level. (E) There was a significantly negative correlation between the expression level of SENP3-EIF4A1 and the expression level of miR-9-5p in the same paired HCC samples. (F) There was a significantly negative correlation between the expression level of ZFP36 and the expression level of miR-9-5p in the same paired HCC samples. (G) ZFP36 in HuH7 and Hep3b cells with SENP3-EIF4A1-Exos and/or miR-9-5p mimics examined via Western blotting. (H) ZFP36 in SMMC-7721 cells with SENP3-EIF4A1 siRNA-Exos and/or miR-9-5p inhibitor examined via Western blotting. Data are shown as mean ± SD. *P<0.05. All of the experiments were performed in triplicate.
Figure 7Effects of HuH7 cells are transfected with SENP3-EIF4A1/NC lentiviral vectors, namely SENP3-EIF4A1 vectors and NC, respectively. Exos are separated from HL-7702 cells transfected with SENP3-EIF4A1/NC lentiviral vectors, namely SENP3-EIF4A1-Exos and NC-Exos, respectively. (A) The xenografts from nude mice inoculated in NC, SENP3-EIF4A1-Exos, SENP3-EIF4A1 vectors and NC-Exos (n=5, each group). (B) The tumor volumes are measured every other day after injection. (C) Determination of the tumor weights in nude mice after 15 days. (D) Detection of SENP3-EIF4A1 expression in tumor tissues of nude mice treated with NC, SENP3-EIF4A1 vectors, SENP3-EIF4A1-Exos and NC-Exos by qRT-PCR. (E) Detection of ZFP36 in tumor tissues via Western blotting. (F) Analysis of ZFP36 expression in tumor tissues by IHC. Results are shown as mean ± SD. *P<0.05.